Yinchuan, China – 16 Sep 2026 – The Ningxia Hui Autonomous Region Medical Products Administration (Ningxia MPA) issued the Implementation Plan for the “Spring Rain Action” (2026–2028) to Transform Clinical Innovation Achievements of Medical Devices (Ningyao Jianfa [2026] No. 44), a three‑year program that solicits clinician‑originated device innovations and channels them through screening, matchmaking, cultivation and registration support — with joint execution by the region’s industry & IT, health and market regulation departments — aiming to bring a batch of med‑engineering integrated landmark products to market.
Policy Snapshot
| Item | Detail |
|---|---|
| Authority | Ningxia Hui Autonomous Region MPA (lead), with Department of Industry & Information Technology, Health Commission, Market Regulation Department |
| Document | “Spring Rain Action” (2026–2028) Implementation Plan – Ningyao Jianfa [2026] No. 44 |
| Objective | Convert clinical innovation achievements into registered medical devices; build an ecosystem of “clinical idea supply – med‑engineering collaborative R&D – central‑local nurturing – cross‑department promotion” |
| Horizon | Three years: 2026–2028 |
| Mechanism | Full‑chain workflow: collection & screening → matchmaking → coaching & cultivation → commercialization |
| Original Document | nxyjj.nx.gov.cn (published 16 September 2026) |
Program Architecture – Five Phases
- Organizational Preparation (Sept 2026): Joint issuance of the plan; four departments each appoint a liaison to coordinate daily work.
- Policy Promotion (Sept–Oct 2026): Online publicity plus offline consultation targeting medical institutions at all levels; on‑site policy briefings in device industrial parks; a dedicated “Spring Rain Action” column on the MPA website to publicize screening progress.
- Collection & Screening (Nov 2026 – Nov 2027): Medical institutions submit convertible clinical innovations via the official Project Information Collection Form; the Ningxia MPA drafts Clinical Value Screening Evaluation Criteria for joint departmental approval, screens projects, and publicizes selected entries (with applicant consent).
- Matchmaking (Dec 2027 – Jun 2028): Multi‑department project matchmaking sessions connect hospitals, research institutes and interested companies/investors; enterprises file an Intent Matching Form, and converted products are reported via a Converted Product List.
- Product Cultivation (Jun 2028 – Dec 2028, continuing per R&D cycles): Projects entering development are designated key cultivation products under an “active outreach, one‑product‑one‑policy, full‑course tracking, dedicated team support” regime — with Class I/II devices guided through R&D, registration and filing, and Class III candidates (especially innovative/priority‑review products) recommended to the NMPA Center for Medical Device Evaluation for pre‑review services and to national “open competition for best candidates” and key R&D programs.
Roles & Responsibilities
- Ningxia MPA (lead): Sets screening criteria; provides pre‑review consultation, standards research, product design optimization, testing, clinical trial guidance and R&D‑review linkage services; reports progress regularly to the NMPA.
- Industry & IT Department: Mobilizes regional industrial resources; drives precise hospital‑enterprise matchmaking; supports capacity and market expansion.
- Health Commission: Encourages medical institutions to open clinical trial resources and submit qualifying innovation projects; supports registration studies.
- Market Regulation Department: Provides patent guidance — conversion, layout and infringement disputes — including a patent pre‑examination fast track for projects in new materials and high‑end equipment manufacturing.
- Hospitals & Clinicians: Ensure research compliance, ethics review and subject protection; submit and drive clinical innovation projects; institutionalize成果转化 mechanisms.
- Device Companies & Investors: Negotiate investment or IP transfer agreements; jointly complete product finalization, clinical trials, registration and compliant production.
Market Impact & Outlook
- Translation Gap Addressed: The program directly targets the “valley of death” between clinician ideas and registered products — pairing clinical demand with engineering and regulatory coaching rarely available to individual practitioners.
- Regional Innovation Signal: For a western region with a smaller medtech base, dedicated provincial‑level translation machinery plus links to NMPA pre‑review channels is a meaningful incentive for device developers and hospital innovators in Ningxia.
- Regulatory Fast‑Track Access: Projects preliminarily identified as Class III innovative or priority‑review candidates may reach national‑level review support — the most consequential carrot in the plan for high‑value products.
- Monitoring Cadence: Departments file biannual progress reports (by 15 May and 15 Nov annually) to the Ningxia MPA, which consolidates and reports to the NMPA by end of May and November — creating a built‑in disclosure rhythm for tracking program results through 2028.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation of Ningxia’s “Spring Rain Action” program, including project screening outcomes, product development timelines and potential registration milestones. Actual results depend on project quality, departmental coordination, regulatory reviews and market conditions, and may differ materially from current expectations.-China Health Reform Pulse
Policy Source: http://nxyjj.nx.gov.cn/zwgk/gkml/zcwj11/gzwj_37845/zcfgc/202609/t20260916_5344613.html